ASAngelika Schütz

Angelika Schütz

*This is an algorithmically generated author record based on publicly available information.

Angelika Schütz has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    CHIME - A tailored HCV microelimination project in Viennese people who inject drugs at drug centralized substitution centers

    by Caroline Schwarz, Raphael Schubert, Michael Schwarz, Angelika Schütz, Anika Jenke, David Bauer, Benjamin Steinwender, Enisa Gutic, Thomas Reiberger, Hans Haltmayer, et al.


  • Open Access

    Combining treatment for chronic hepatitis C with opioid agonist therapy is an effective microelimination strategy for people who inject drugs with high risk of non-adherence to direct-acting antiviral therapy

    by M. Schwarz, C. Schwarz, A. Schütz, C. Schwanke, E. Krabb, R. Schubert, S.-T. Liebich, D. Bauer, L. Burghart, L. Brinkmann, et al.


  • Open Access

    Combining Treatment for Chronic Hepatitis C with Opioid Agonist Therapy is an Effective Microelimination Strategy for People Who Inject Drugs with High Risk of Non-Adherence to Antiviral Therapy

    by Michael Schwarz, Caroline Schwarz, Angelika Schütz, Cornelia Schwanke, Eva Krabb, Raphael Schubert, Sophie-Therese Liebich, David Bauer, Lukas Burghart, Leonard Brinkmann, et al.

    Background & Aims: Despite effective direct-acting antivirals (DAAs), hepatitis C virus (HCV) prevalence is high among people who inject drugs (PWIDs) and non-adherence to therapy remains a major obstacle towards HCV elimination in this subpopulation. To overcome this, we combined ongoing opioid agonist therapy (OAT) with direct-acting antivirals (DAA) in a directly-observed therapy (DOT) setting. Method: From September 2014 until January 2021 PWIDs at high risk for non-adherence to DAA therapy were included in this microelimination project. PWIDs received HCV treatment alongside their OAT under supervision of healthcare workers in a pharmacy or low-threshold facility. Results: In total, 522 HCV-RNA-positive PWIDs (400 men, 76.6%; median age: 38 years [IQR 12], HIV: 4.4%; HBV: 1.3%) were included. Of these, 308/491 patients (62.7%) reported ongoing IDU (intravenous drug use). Following the concept of DOT, adherence to DAA treatment was excellent (missed appointments: 90/25,792, 0.4%). Forty-one (7.9%) patients were lost to follow-up. Two (0.4%) patients died due to reasons unrelated to DAA treatment. SVR12 was achieved in 457/461 (99.1%; 95% CI: 98.3-100.0%) patients, while only 4/461 (0.9%) patients showed treatment failure (modified intention-to-treat, mITT). Over a median follow-up of 24 (IQR 27) weeks, reinfections were observed in 27/457 (5.9%) patients. Conclusions: Coupling DAA treatment to OAT in a DOT setting resulted in SVR12 rates greater than 99% in PWIDs at high risk for non-adherence to therapy despite high rates of IDU. Importantly, only 7.9% of the patients were lost to follow-up, but finished DAA therapy. Competing Intrerest Statement: Michael Schwarz, Austria (schwarz.medizin@gmail.com): received speaking honoraria from BMS and travel support from BMS, AbbVie, Gilead, and MSD. - Caroline Schwarz, Austria (schwarz.caroline1990@gmail.com): received travel support from Gilead, Abbvie, and Gebro; speaking honoraria from Abbvie and Gilead; and served as a consultant for Gilead. Angelika Schütz, Austria (angelika.schuetz@suchthilfe.at): no conflicts of interest. Cornelia Schwanke, Austria (cornelia.schwanke@suchthilfe.at): no conflicts of interest. Eva Krabb, Austria (eva.krabb@suchthilfe.at) no conflicts of interest. Raphael Schubert, Austria (raphael.schubert@outlook.at): received travel support from Gilead. Sophie-Therese Liebich, Austria (sophie-therese.liebich@suchthilfe.at): no conflicts of interest. David Bauer (david.bauer@meduniwien.ac.at): received travel support from Gilead and Abbvie and speaker fees from Abbvie. Lukas Burghart (lukas.burghart@gesundheitsverbund.at): no conflicts of interest. Leonard Brinkmann (leonard-ruben.brinkmann@gesundheitsverbund.at): no conflicts of interest. Enisa Gutic, Austria (enisa.gutic@extern.gesundheitsverbund.at): received travel support from Gilead and AbbVie. Thomas Reiberger, Austria (thomas.reiberger@meduniwien.ac.at): received grant support from Abbvie, Boehringer-Ingelheim, Gilead, MSD, Philips Healthcare, Gore; speaking honoraria from Abbvie, Gilead, Gore, Intercept, Roche, MSD; consulting/advisory board fee from Abbvie, Bayer, Boehringer-Ingelheim, Gilead, Intercept, MSD, Siemens; and travel support from Boehringer-Ingelheim, Gilead and Roche. Hans Haltmayer, Austria (hans.haltmayer@suchthilfe.at): no conflicts of interest. - Michael Gschwantler, Austria (michael.gschwantler@gesundheitsverbund.at): received grant support from Abbvie, Gilead and MSD; speaking honoraria from Abbvie, Gilead, Intercept, Janssen, BMS, Roche, Norgine, AstraZeneca, Falk, Shionogi, and MSD; consulting/advisory board fees from Abbvie, Gilead, Intercept, Janssen, BMS, Roche, Alnylam, Norgine, AstraZeneca, Falk, Shionogi and MSD; and travel support from Abbvie and Gilead.

  • Open Access

    Directly observed therapy at opioid substitution facilities using sofosbuvir/velpatasvir results in excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapy

    by Caroline Schmidbauer, Michael Schwarz, Angelika Schütz, Raphael Schubert, Cornelia Schwanke, Enisa Gutic, Roxana Pirker, Tobias Lang, Thomas Reiberger, Hans Haltmayer, et al.

    We evaluated the effectiveness of sofosbuvir/velpatasvir (SOF/VEL) in difficult-to-treat PWIDs with presumed high risk for non-adherence to antiviral therapy using an innovative concept involving their opioid agonist therapy (OAT) facility. N = 221 patients (m/f: 168/53; median age: 44.7 years (IQR 16.9); HCV-genotype 3: 45.2%; cirrhosis: 33.9%) treated with SOF/VEL were included. PWIDs at high risk for non-adherence to DAA therapy (n = 122) received HCV treatment alongside OAT under the supervision of medical staff ("directly observed therapy", DOT). These patients were compared to patients with presumed excellent drug compliance, who were treated in a "standard setting" (SS) of SOF/VEL prescription at a tertiary care center (n = 99). DOT-patients (n = 122/221; 55.2%) were younger than SS-patients (median age: 41.3 vs. 53.0 years), all had psychiatric comorbidities and most had a poor socioeconomic status. 83/122 (68.0%) reported ongoing intravenous drug use. Within the DOT-group, SVR12 was achieved in 99.1% (95% CI: 95.0–100; n = 109/110) with one patient experiencing treatment failure, while n = 12/122 (9.8%) patients were excluded due to loss of follow-up (FU). 5 patients showed HCV reinfection after achieving SVR12. SS-patients achieved SVR in 96.6% (95% CI: 90.3–99.3%; n = 84/87) after exclusion of 10/99 (10.1%) patients who were lost to FU and 2 patients who died prior to SVR12 due to reasons not related to DAA therapy. SOF/VEL given as DOT along with OAT in PWIDs at high risk of non-adherence to antiviral therapy including those with ongoing intravenous drug use resulted in excellent SVR rates similar to patients with presumed “excellent compliance” under standard drug intake.


  • Open Access

    Directly observed therapy for HCV with glecaprevir/pibrentasvir alongside opioid substitution in people who inject drugs—First real world data from Austria

    by Caroline Schmidbauer, Raphael Schubert, Angelika Schütz, Cornelia Schwanke, Julian Luhn, Enisa Gutic, Roxana Pirker, Tobias Lang, Thomas Reiberger, Hans Haltmayer, et al.

    Directly acting antivirals (DAA) against hepatitis C virus (HCV) infection have facilitated sustained virologic response (SVR) rates >90% in clinical studies. Yet, real life data regarding DAA treatment in people who inject drugs (PWIDs) are scarce. We evaluated the effectiveness of glecaprevir/pibrentasvir (G/P) in difficult-to-treat PWIDs with presumed high risk of non-adherence to DAA therapy using the concept of directly observed therapy involving their opioid substitution therapy (OST) facility. N = 145 patients (m/f: 91/54; median age: 41.1 (IQR 19.5) years; HCV-genotype (GT) 1/2/3/4: 82/1/56/5, GT3: 38.6%; cirrhosis: n = 6; 4.1%) treated with G/P were included. PWIDs at high risk for non-adherence to DAA therapy received HCV treatment together with their OST under the supervision of medical staff ("directly observed therapy", DOT). The effectiveness of G/P given as DOT in PWIDs with presumed high risk of non-adherence to DAA therapy was compared to patients with suspected “excellent compliance” in the "standard setting" (SS) of G/P prescription at a tertiary care center and self-managed G/P intake at home. Treatment duration was 8–16 weeks according to the G/P drug label. DOT-patients (n = 74/145; 51.0%) were younger than SS-patients (median 38.7, IQR 12.5 vs. median 50.6, IQR 20.3 years), all had psychiatric co-morbidities and most had a poor socioeconomic status. 50/74 (67.6%) reported ongoing intravenous drug use (IDU). SVR was achieved in n = 70/74 (94.6%) patients with n = 3 being lost to follow-up (FU) and n = 1 showing nonresponse to therapy. SS-patients achieved SVR in 97.2% (69/71) with n = 1 patient being lost to FU and n = 1 patient with GT3 showing HCV relapse. G/P given as DOT along with OST in PWIDs with high risk of non-adherence to DAA therapy resulted in similarly high SVR rates (94.6%) as in patients with presumed “excellent compliance” under standard drug intake.